Document Detail


Celecoxib and radioresistant glioblastoma-derived CD133+ cells: improvement in radiotherapeutic effects. Laboratory investigation.
MedLine Citation:
PMID:  21054139     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECT: Glioblastoma, the most common primary brain tumor, has a poor prognosis, even with aggressive resection and chemoradiotherapy. Recent studies indicate that CD133(+) cells play a key role in radioresistance and recurrence of glioblastoma. Cyclooxygenase-2 (COX-2), which converts arachidonic acid to prostaglandins, is over-expressed in a variety of tumors, including CD133(+) glioblastomas. The COX-2-derived prostaglandins promote neovascularization during tumor development, and conventional radiotherapy increases the proportion of CD133(+) cells rather than eradicating them. The aim of the present study was to investigate the role of celecoxib, a selective COX-2 inhibitor, in enhancing the therapeutic effects of radiation on CD133(+) glioblastomas.
METHODS: Cells positive for CD133 were isolated from glioblastoma specimens and characterized by flow cytometry, then treated with celecoxib and/or ionizing radiation (IR). Clonogenic assay, cell irradiation, cell cycle analysis, Western blot, and xenotransplantation were used to assess the effects of celecoxib alone, IR alone, and IR with celecoxib on CD133(+) and CD133(-) glioblastoma cells. Three separate xenotransplantation experiments were carried out using 310 severe combined immunodeficient (SCID) mice: 1) an initial tumorigenicity evaluation in which 3 different quantities of untreated CD133(-) cells or untreated or pretreated CD133(+) cells (5 treatment conditions) from 7 different tumors were injected into the striatum of 2 mice (210 mice total); 2) a tumor growth study (50 mice); and 3) a survival study (50 mice). For these last 2 studies the same 5 categories of cells were used as in the tumorigenicity (untreated CD133(-) cells, untreated or pretreated CD133(+) cells, with pretreatment consisting of celecoxib alone, IR alone, or IR and celecoxib), but only 1 cell source (Case 2) and quantity (5 × 10(4) cells) were used.
RESULTS: High levels of COX-2 protein were detected in the CD133(+) but not the CD133(-) glioblastoma cells. The authors further demonstrated that 30 μM celecoxib was able to effectively enhance the IR effect in inhibiting colony formation and increasing IR-mediated apoptosis in celecoxib-treated CD133(+) glioblastoma cells. Furthermore, reduction in radioresistance was correlated with the induction of G2/M arrest, which was partially mediated through the increase in the level of phosphorylated-cdc2. In vivo xenotransplant analysis further confirmed that CD133(+)-associated tumorigenicity was significantly suppressed by celecoxib treatment. Importantly, pretreatment of CD133(+) glioblastoma cells with a combination of celecoxib and IR before injection into the striatum of SCID mice resulted in a statistically significant reduction in tumor growth and a statistically significant increase in the mean survival rate of the mice.
CONCLUSIONS: Celecoxib combined with radiation plays a critical role in the suppression of growth of CD133(+) glioblastoma stemlike cells. Celecoxib is therefore a radiosensitizing drug for clinical application in glioblastoma.
Authors:
Hsin-I Ma; Shih-Hwa Chiou; Dueng-Yuan Hueng; Lung-Kuo Tai; Pin-I Huang; Chung-Lan Kao; Yi-Wei Chen; Huey-Kang Sytwu
Related Documents :
8211379 - Sensitivity of roberts syndrome cells to gamma radiation, mitomycin c, and protein synt...
3975359 - Effect of misonidazole on formation of thymine damage by gamma rays.
19346679 - Ceramide induces myogenic differentiation and apoptosis in drosophila schneider cells.
20095849 - Amifostine metabolite wr-1065 disrupts homologous recombination in mammalian cells.
11182789 - The bystander effect in radiation oncogenesis: i. transformation in c3h 10t1/2 cells in...
20128919 - Loratadine dysregulates cell cycle progression and enhances the effect of radiation in ...
19875929 - Mg-protoporphyrin ix signaling in cyanidioschyzon merolae: multiple pathways may involv...
6407159 - Incompatibility associated with the bite of a brown recluse spider (loxosceles reclusa).
15648789 - Mitochondrial membrane potential change induced by hoechst 33342 in myelogenous leukemi...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2010-11-05
Journal Detail:
Title:  Journal of neurosurgery     Volume:  114     ISSN:  1933-0693     ISO Abbreviation:  J. Neurosurg.     Publication Date:  2011 Mar 
Date Detail:
Created Date:  2011-03-02     Completed Date:  2011-04-22     Revised Date:  2014-07-30    
Medline Journal Info:
Nlm Unique ID:  0253357     Medline TA:  J Neurosurg     Country:  United States    
Other Details:
Languages:  eng     Pagination:  651-62     Citation Subset:  AIM; IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Animals
Antigens, CD / metabolism*
Antineoplastic Agents / pharmacology*
Apoptosis / drug effects
Blotting, Western
Brain Neoplasms / drug therapy*,  enzymology,  radiotherapy*
Cell Division / drug effects
Cell Line, Tumor
Cell Separation
Culture Media
Cyclooxygenase 2 / biosynthesis
Drug Resistance, Neoplasm
Flow Cytometry
Fluorescent Antibody Technique
G2 Phase / drug effects
Glioblastoma / drug therapy*,  enzymology,  radiotherapy*
Glycoproteins / metabolism*
Humans
In Situ Nick-End Labeling
Male
Mice
Mice, SCID
Middle Aged
Neoplastic Stem Cells / drug effects,  radiation effects
Peptides / metabolism*
Pyrazoles / pharmacology*
Sulfonamides / pharmacology*
Survival Analysis
Up-Regulation
Xenograft Model Antitumor Assays
Chemical
Reg. No./Substance:
0/AC133 antigen; 0/Antigens, CD; 0/Antineoplastic Agents; 0/Culture Media; 0/Glycoproteins; 0/Peptides; 0/Pyrazoles; 0/Sulfonamides; 169590-42-5/celecoxib; EC 1.14.99.1/Cyclooxygenase 2
Comments/Corrections
Comment In:
J Neurosurg. 2011 Mar;114(3):648; discussion 648-50   [PMID:  21054138 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Editorial Finding drugs against CD133(+) glioma subpopulations.
Next Document:  Extended endoscopic endonasal approach for selected pituitary adenomas: early experience.